NCT02362464View on ClinicalTrials.gov

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Prostatic NeoplasmsNeoplasms of ProstateProstate CancerCancer Of ProstateStage D0 Prostate Cancer
Interventions
BIOLOGICAL

Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine

dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02362464 - Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 | Biotech Hunter | Biotech Hunter